Natera Q2 earnings: Medicare expansion and Japan's approval could offset revenue dip

cn.investing.com (Chinese)

Natera reports Q2 earnings Thursday after market close, with investors focused on whether Medicare reimbursement expansion for its flagship Signatera cancer test can offset revenue pressure. Analysts expect revenue of $661.3 million, up 21% year over year but down from $696.6 million last quarter, with a per-share loss of 49 cents, narrowing from 60 cents. The stock trades near its 52-week high at $274.62. In June, NCCN gave Signatera a Level 1 recommendation for bladder cancer. CMS is considering expanding Medicare coverage to seven additional cancer types, and Japan approved reimbursement in the second quarter.


With a significance score of 1, this news ranks in the top 65% of today's 33236 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: